Pharmacogenomics Market Size, Share, Growth, Industry Analysis, Trends and Dynamics, By Types (DNA Sequencing, Microarray, Polymerase Chain Reaction, Electrophoresis, Mass Spectrometry, Others), By Applications (Drug Discovery, Tailored Treatment, Oncology, Pain Management, Other Therapeutic Applications), Regional Insights and Forecast to 2035
- Last Updated: 18-November-2026
- Base Year: 2025
- Historical Data: 2021 - 2024
- Region: Global
- Format: PDF
- Report ID: GGI114061
- SKU ID: 30522468
- Pages: 107
Download FREE Sample
Pharmacogenomics Market Size
The Global Pharmacogenomics Market size was USD 8340.5 Million in 2025 and is projected to reach USD 9155.33 Million in 2026 and USD 10049.9 Million in 2027, advancing to USD 21190.89 Million by 2035. The market is expected to exhibit a CAGR of 9.77% during the forecast period from 2026 to 2035, reflecting sustained adoption of genotype-guided prescribing, broader clinical testing, and increasing integration of genomic information into drug development and treatment decisions.
The market is being shaped by the shift from broad treatment protocols toward more individualized therapeutic decisions. Pharmacogenomic testing is increasingly positioned as a practical tool for identifying drug-response differences, minimizing avoidable adverse reactions, and supporting dose selection. Approximately 9% of the market's projected growth profile is associated with the expanding use of molecular testing, while nearly 6% of clinical workflows are increasingly incorporating genetic information into treatment-selection processes.
![]()
US Pharmacogenomics Market growth is supported by established molecular diagnostic infrastructure, strong precision-medicine programs, and increasing clinical awareness of genotype-based prescribing. Around 11% of U.S. precision-care workflows increasingly emphasize genomic information, while roughly 7% of healthcare testing demand is linked to applications involving personalized treatment and medication-response assessment. Payer coverage, clinical utility evidence, and standardized interpretation remain important factors influencing adoption.
In the US Pharmacogenomics Market, adoption is particularly relevant across oncology, psychiatry, cardiology, and pain management, where differences in drug metabolism and response can materially influence therapy selection. Approximately 8% of clinical testing activity is associated with medication-response applications, while nearly 5% of healthcare organizations are expanding genomic decision-support capabilities.
Key Findings
- Market Size: Starting at USD 9155.33 Million in 2026, the market is projected to reach USD 10049.9 Million in 2027 and USD 21190.89 Million by 2035 at a CAGR of 9.77%.
- Growth Drivers: Precision prescribing, genomic testing, and clinical decision support are strengthening adoption, with approximately 9% and 7% growth-related indicators across expanding clinical applications.
- Trends: Sequencing, PCR, automated interpretation, and multi-gene panels are gaining importance, with adoption indicators of approximately 10% and 6% across emerging workflows.
- Key Players: Abbott Laboratories, Inc, Bayer AG, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche AG, Becton, Dickinson and Company & more.
- Regional Insights: North America accounts for 38%, Europe 27%, Asia-Pacific 25%, and Middle East & Africa 10%, reflecting differences in testing infrastructure and precision-medicine adoption.
- Challenges: Testing costs, reimbursement variability, interpretation complexity, and limited specialist capacity constrain adoption, with approximately 8% and 5% impact indicators across major implementation barriers.
- Industry Impact: Pharmacogenomic testing is strengthening precision prescribing and clinical trial design, while approximately 9% of workflows increasingly emphasize personalized therapeutic decisions and 6% prioritize genomic decision support.
- Recent Developments: Assay expansion, automated workflows, bioinformatics, and pharmacogenomic knowledgebases are advancing the market, with development activity showing approximately 10% and 7% emphasis on testing efficiency and interpretation.
The Pharmacogenomics Market is increasingly moving from research-oriented genetic analysis toward clinically actionable testing. Its commercial direction is influenced by the ability of laboratories and healthcare providers to convert genetic findings into clear medication decisions. Around 8% of adoption momentum is linked to clinical workflow integration, while approximately 6% reflects growing demand for scalable genomic interpretation.
Competitive positioning is increasingly determined by assay breadth, analytical reliability, workflow automation, and the ability to connect test results with therapeutic guidance. Approximately 7% of industry activity is concentrated around expanding molecular testing capabilities, while nearly 5% is associated with improving data interpretation and clinical usability.
![]()
Pharmacogenomics Market Trends
The Pharmacogenomics Market is evolving alongside the wider movement toward precision medicine. Testing is increasingly used to identify genetic variants that influence drug metabolism, therapeutic response, or toxicity risk. PCR and sequencing remain important because they can support targeted and multi-gene testing across different clinical settings. Around 10% of market activity is increasingly associated with broader molecular profiling, while approximately 7% reflects demand for more efficient interpretation of genetic results. The growing availability of automated laboratory systems is also changing the economics of testing by reducing manual processing requirements and improving consistency. Multi-gene panels are gaining attention because a single workflow can evaluate several clinically relevant variants rather than requiring separate tests. This makes pharmacogenomic testing more practical for complex medication histories and multidisciplinary care.
Another important trend is the integration of pharmacogenomics with digital clinical decision support. Genetic information becomes more useful when laboratory findings can be translated into actionable medication recommendations through structured interpretation systems. Approximately 8% of adoption momentum is connected with data interpretation and decision-support capabilities, while nearly 6% relates to increasing use of automated and standardized laboratory workflows. Oncology remains an important area because treatment response and toxicity can vary substantially between patients, but psychiatry, cardiology, pain management, and other therapeutic areas are also expanding the addressable opportunity. The market is therefore shifting toward integrated testing ecosystems that combine sample preparation, genotyping, sequencing, interpretation, and clinical implementation.
Pharmacogenomics Market Dynamics
Expansion of Precision Treatment
The strongest opportunity lies in embedding pharmacogenomic testing into routine medication decisions rather than limiting testing to specialist research settings. As healthcare providers increasingly seek measurable improvements in treatment selection, testing can become part of standardized clinical pathways. Approximately 9% of opportunity indicators are associated with broader precision-care adoption, while around 6% relate to expanding use across oncology, psychiatry, cardiology, and pain management. Broader access to automated testing and clearer interpretation can further reduce implementation friction. The opportunity is particularly attractive where adverse drug reactions, treatment failure, or dose variability create significant clinical and operational costs. Continued development of multi-gene panels may also improve testing efficiency by providing several clinically relevant results from one patient sample.
Growing Use of Genotype-Guided Prescribing
The primary growth driver is the increasing recognition that genetic differences can influence drug metabolism, efficacy, and toxicity. Healthcare systems are progressively incorporating genomic information into personalized treatment strategies, especially where medication response varies substantially between patients. Approximately 10% of demand indicators are associated with expanding molecular testing, while around 7% reflect increasing interest in genotype-guided treatment decisions. Improvements in PCR, sequencing, microarray, and interpretation technologies are making testing more accessible to laboratories with different levels of technical capacity. The driver is strengthened by the growing emphasis on reducing avoidable adverse reactions and improving treatment precision. As clinical evidence accumulates, pharmacogenomics is increasingly viewed as a practical component of precision healthcare rather than solely a research technology.
| Market Driver | Impact Rank | Contribution | 2026-2028 | 2029-2031 | 2032-2035 |
|---|---|---|---|---|---|
| Expansion of genotype-guided prescribing | High | 13.40% | High | High | Medium |
| Growth of precision medicine and personalized treatment | High | 10.20% | High | High | High |
| Advances in sequencing and molecular testing | Medium | 8.10% | High | Medium | Medium |
| Increasing adoption of automated genomic interpretation | Medium | 5.90% | Medium | High | Medium |
| Expansion into oncology and other therapeutic applications | Low | 3.80% | Medium | Medium | High |
| Others | Lowest | 1.20% | Low | Low | Medium |
| Total Driver Contribution | 42.60% |
RESTRAINTS
"Testing Cost and Reimbursement Variability"
Cost remains a meaningful restraint because pharmacogenomic testing requires laboratory infrastructure, specialized reagents, trained personnel, and reliable interpretation. Approximately 8% of implementation barriers are associated with affordability and reimbursement limitations, while around 5% relate to differences in payer policies and clinical coverage criteria. These issues can delay adoption even when physicians recognize the potential value of testing. Smaller hospitals and laboratories may face additional challenges because they often lack dedicated genomic expertise or high-throughput equipment. The situation is gradually improving as testing workflows become more automated and targeted assays reduce unnecessary analytical complexity, but widespread adoption still depends on stronger evidence of clinical utility, clearer reimbursement pathways, and standardized interpretation practices.
| Market Restraint | Impact Rank | Negative CAGR Impact | 2026-2028 | 2029-2031 | 2032-2035 |
|---|---|---|---|---|---|
| High testing and laboratory implementation costs | High | -1.50% | High | Medium | Low |
| Inconsistent reimbursement and coverage policies | Medium | -0.90% | High | Medium | Low |
| Limited genomic interpretation expertise | Low | -0.60% | Medium | Medium | Low |
| Others | Lowest | -0.30% | Low | Low | Low |
| Total Restraint Impact | -3.30% |
CHALLENGES
"Clinical Interpretation and Implementation Complexity"
Pharmacogenomic testing produces meaningful value only when genetic findings can be accurately interpreted and translated into treatment decisions. Approximately 7% of implementation challenges are associated with interpretation complexity, while around 5% relate to shortages of personnel with both genomic and clinical expertise. Laboratories must maintain analytical quality, variant databases, reporting standards, and secure patient-data processes. Differences in testing methodologies can also complicate result comparison between facilities. Another challenge is ensuring that genetic findings remain clinically relevant as evidence and prescribing guidance evolve. The market therefore requires continuing investment in interpretation systems, clinician education, standardized reporting, and interoperable decision-support tools. Stronger integration between laboratories and healthcare systems can reduce these barriers and improve confidence in routine use.
Segmentation Analysis
The Pharmacogenomics Market is segmented by technology and application, with each category addressing a different stage of genomic testing and clinical utilization. Technology selection depends on the number of variants required, testing throughput, analytical sensitivity, and laboratory infrastructure. Application demand is influenced by therapeutic complexity and the need to reduce medication-response variability. Around 10% of market activity is increasingly linked to advanced molecular workflows, while approximately 7% is associated with applications requiring personalized treatment decisions.
By Type
DNA Sequencing
DNA Sequencing is increasingly important for pharmacogenomic analysis because it can evaluate multiple genes and variant types within broader genomic workflows. Its value is strongest where complex genetic profiles must be assessed rather than a small number of predefined markers. Approximately 11% of technology adoption indicators are associated with expanded sequencing-based workflows, while around 7% reflect demand for broader multi-variant analysis. Continued improvements in throughput, sample preparation, and interpretation are helping sequencing become more practical for clinical applications.
Microarray
Microarray technology remains relevant for high-volume genotyping where established marker sets can provide efficient and reproducible results. It is particularly useful for applications requiring analysis of numerous predefined genetic variants across large patient groups. Approximately 8% of technology demand indicators relate to scalable genotyping workflows, while nearly 6% reflect continued interest in cost-efficient multi-marker analysis. Automated processing and improved array content are supporting its role in research and selected clinical pharmacogenomic applications.
Polymerase Chain Reaction
Polymerase Chain Reaction remains a practical technology for targeted pharmacogenomic testing because it can provide rapid analysis of specific variants with comparatively straightforward laboratory workflows. PCR is well suited to settings where clinicians require focused information for a particular medication or therapeutic pathway. Approximately 10% of technology adoption indicators relate to targeted molecular testing, while around 7% reflect demand for faster laboratory turnaround. Its compatibility with established diagnostic infrastructure supports continued use across hospitals and specialized testing laboratories.
Electrophoresis
Electrophoresis continues to support selected genetic analysis workflows where separation and visualization of amplified or processed nucleic-acid products remain useful. Although more advanced platforms increasingly handle complex genomic profiling, electrophoresis can remain valuable in laboratories requiring accessible analytical methods. Approximately 5% of workflow demand indicators are associated with conventional molecular separation, while around 3% relate to supporting laboratory applications. Its role is therefore more specialized than sequencing or PCR, but it continues to contribute to complementary testing workflows.
Mass Spectrometry
Mass Spectrometry offers a high-precision approach for analyzing molecular characteristics associated with drug response and genetic variation. Its analytical strength makes it relevant where laboratories require sensitive and reproducible measurements. Approximately 6% of advanced testing indicators are associated with mass-spectrometry-based workflows, while about 4% reflect demand for high-resolution molecular analysis. Adoption depends on instrument availability, laboratory expertise, and workflow economics, but continued improvements in automation can strengthen its contribution to specialized pharmacogenomic testing.
Others
Other technologies include complementary molecular and computational methods that support pharmacogenomic research, validation, and clinical interpretation. These approaches can fill workflow gaps where conventional sequencing, PCR, microarray, electrophoresis, or mass spectrometry are not optimal. Approximately 4% of technology activity is associated with emerging or complementary methods, while nearly 3% reflects specialized laboratory requirements. Their importance is expected to increase where integrated testing platforms combine multiple analytical approaches into a single clinical workflow.
By Application
Drug Discovery
Drug Discovery is an important application because pharmacogenomic information can help researchers identify genetic factors associated with efficacy, toxicity, and treatment response. Incorporating genomic stratification can improve patient selection and strengthen the design of targeted therapeutic programs. Approximately 9% of application indicators relate to genomic-supported drug research, while around 6% reflect demand for biomarker-driven development. The application benefits from growing integration between genomic testing, molecular profiling, and clinical trial analytics, enabling researchers to identify patient populations more likely to respond to specific therapies.
Tailored Treatment
Tailored Treatment represents a core application because it connects genetic information directly with medication selection and dosing decisions. Healthcare providers can use pharmacogenomic findings to identify patients who may metabolize certain medicines differently or face elevated toxicity risks. Approximately 11% of application adoption indicators are associated with personalized treatment strategies, while nearly 8% relate to clinical decision support. Broader implementation depends on physician education, reimbursement, standardized interpretation, and convenient access to testing. As these conditions improve, tailored treatment is expected to remain one of the strongest practical applications.
Oncology
Oncology is a high-value application because cancer treatment frequently depends on molecular characteristics and individual response patterns. Pharmacogenomic information can support decisions involving drug metabolism, toxicity risk, and treatment selection. Approximately 10% of application activity is linked with oncology-related genomic testing, while around 7% reflects increasing interest in molecularly informed treatment strategies. The application also benefits from the wider adoption of multi-gene panels and sequencing platforms that can assess several relevant biomarkers from limited patient samples.
Pain Management
Pain Management offers an important opportunity for pharmacogenomics because patients can differ considerably in their response to analgesics and other medications. Genetic differences affecting drug metabolism can contribute to variation in therapeutic effectiveness and adverse reactions. Approximately 6% of application indicators relate to personalized pain-treatment strategies, while around 4% reflect growing interest in medication-response testing. Adoption remains dependent on clinical evidence and physician confidence, but improved interpretation tools can make pharmacogenomic information more practical for individualized prescribing.
Other Therapeutic Applications
Other Therapeutic Applications encompass cardiovascular, psychiatric, neurological, and additional treatment areas where genetic variation can influence drug response. Diversification beyond oncology is important because it expands the clinical base of pharmacogenomic testing. Approximately 8% of application indicators are associated with these broader therapeutic areas, while around 5% reflect expanding interest in genotype-guided medication management. Continued clinical validation and standardized treatment recommendations can help move these applications from selective testing toward more consistent integration into routine care.
![]()
Pharmacogenomics Market Regional Outlook
Regional performance differs according to genomic infrastructure, healthcare expenditure, reimbursement, clinical awareness, and availability of specialized laboratories. North America maintains the largest share because of mature precision-medicine capabilities and established testing networks. Europe follows with strong clinical research and molecular diagnostic adoption, while Asia-Pacific is supported by expanding healthcare infrastructure and growing genomic investment. Middle East & Africa remains smaller but presents long-term opportunity as specialized diagnostic capacity expands. The regional shares are structured at 100% overall, with approximately 38% attributed to North America, 27% to Europe, 25% to Asia-Pacific, and 10% to Middle East & Africa.
North America
North America holds a 38% share of the Pharmacogenomics Market and remains the leading regional contributor. Strong genomic testing infrastructure, established molecular diagnostic laboratories, and broad awareness of personalized medicine support adoption. Approximately 12% of regional testing activity is increasingly connected with genotype-guided treatment, while around 8% reflects expanding use of genomic decision-support tools. Oncology, psychiatry, cardiology, and pain management are important application areas. Continued attention to reimbursement and clinical utility is likely to determine how rapidly pharmacogenomic testing moves from specialist programs into broader routine care.
Europe
Europe accounts for 27% of the market and benefits from mature healthcare systems, strong genomic research capabilities, and growing interest in precision medicine. Approximately 9% of regional adoption indicators are linked to personalized prescribing, while around 6% relate to molecular diagnostic expansion. Clinical implementation varies between countries because reimbursement structures and healthcare pathways differ. Research collaborations, standardized laboratory practices, and increasing use of genomic data in therapeutic decision-making continue to support regional development. Europe is also positioned to benefit from greater integration of pharmacogenomics into broader precision-health initiatives.
Asia-Pacific
Asia-Pacific represents 25% of the Pharmacogenomics Market and offers substantial expansion potential as healthcare systems invest in genomic testing and precision medicine. Approximately 10% of regional growth indicators are associated with expanding molecular testing capacity, while around 7% reflect increasing interest in personalized treatment. Large patient populations and growing clinical research activity create a strong base for adoption, although access remains uneven between developed metropolitan systems and emerging healthcare markets. Increasing laboratory automation, falling testing complexity, and broader awareness can strengthen the region's long-term contribution.
Middle East & Africa
Middle East & Africa holds a 10% share and remains an emerging regional market. Adoption is supported by improving diagnostic infrastructure, greater interest in precision medicine, and investment in specialized healthcare capabilities. Approximately 5% of regional demand indicators are associated with genomic testing expansion, while around 3% reflect increasing personalized-care initiatives. Market development remains constrained by limited specialist capacity, uneven access to advanced laboratories, and reimbursement differences. Partnerships involving healthcare providers, laboratories, and research institutions can improve access and strengthen the clinical application of pharmacogenomic testing.
List of Key Pharmacogenomics Market Companies Profiled
- Abbott Laboratories, Inc
- Bayer AG
- Thermo Fisher Scientific Inc.
- F. Hoffmann-La Roche AG
- Becton, Dickinson and Company
- Illumina, Inc.
- Bio-Rad Laboratories, Inc.
- QIAGEN
Top Companies with Highest Market Share
- F. Hoffmann-La Roche AG: Maintains a strong position across molecular diagnostics and genomic testing, supported by approximately 21% share in the broader PCR market and substantial laboratory infrastructure.
- Illumina, Inc.: Holds a leading position in sequencing-related workflows, with approximately 65% share of the clinical NGS market in a cited 2024 market assessment.
Investment Analysis and Opportunities in Pharmacogenomics Market
Investment opportunities are increasingly concentrated around technologies that make pharmacogenomic testing easier to deploy, interpret, and integrate into clinical workflows. Approximately 10% of investment-related opportunity is associated with sequencing and multi-gene testing, while around 7% is linked to automated interpretation and decision-support systems. Investors are also evaluating opportunities in targeted assays because they can address specific therapeutic decisions without requiring the full complexity of broad genomic profiling. Another attractive area is workflow integration, where sample preparation, testing, bioinformatics, and clinical reporting can be combined into streamlined platforms. Expansion into emerging healthcare markets may provide additional opportunities as laboratory capacity improves. Strategic investment is likely to favor companies capable of demonstrating clinical utility, scalable testing economics, and strong interoperability with existing healthcare information systems.
New Products Development
New product development is increasingly focused on improving testing breadth, turnaround time, automation, and clinical interpretation. Approximately 10% of product-development activity is associated with advanced molecular testing and sequencing workflows, while around 7% emphasizes automated analysis and decision support. Recent industry activity includes expanded pharmacogenomic assays, improved genotyping arrays, updated sequencing systems, and specialized knowledgebases. QIAGEN's Pharmacogenomic Insights knowledgebase introduced an advanced resource for understanding how genetic characteristics influence medication response, illustrating the movement toward integrated genomic interpretation. Thermo Fisher has also expanded molecular workflows supporting pharmacogenomic and precision-medicine research. These developments show that product competition is moving beyond analytical accuracy toward complete workflows that connect laboratory testing with clinically useful interpretation.
Recent Developments
- January 2024–Thermo Fisher Scientific expands pangenomic array capabilities: Thermo Fisher introduced the Axiom PangenomiX Array as a broad, more representative genotyping platform designed to support population-scale genetic studies and pharmacogenomic research. The development strengthens access to diverse genetic variation and supports more comprehensive research workflows. Approximately 8% of related technology-development activity is increasingly focused on improving population representation, while around 5% emphasizes broader genomic coverage.
- October 2024–QIAGEN introduces Pharmacogenomic Insights: QIAGEN Digital Insights introduced Pharmacogenomic Insights as a knowledge resource intended to help researchers and translational scientists interpret relationships between genetic characteristics and medication response. The development reflects the industry's growing focus on converting genomic information into usable pharmacogenomic knowledge. Approximately 7% of workflow-development activity is associated with interpretation improvements, while around 5% relates to knowledge-driven clinical translation.
- July 2025–Illumina expands comprehensive oncology profiling capabilities: Illumina launched TruSight Oncology 500 version 2 with expanded genomic profiling capabilities, reduced tissue-input requirements, and workflow improvements. Although positioned primarily for oncology profiling, such capabilities support the broader genomic infrastructure underpinning pharmacogenomic decision-making. Approximately 9% of advanced genomic workflow activity is increasingly focused on broader molecular profiling, while around 6% emphasizes improved sample efficiency.
- October 2025–Thermo Fisher advances automated microarray analysis: Thermo Fisher introduced the SwiftArrayStudio Microarray Analyzer to automate key microarray processing stages and streamline genotype generation. The development is relevant to pharmacogenomic laboratories seeking reproducible, scalable workflows. Approximately 8% of technology adoption indicators are increasingly associated with automation, while around 6% reflect demand for shorter and more standardized laboratory processing.
- 2025–QIAGEN strengthens genomic data and clinical application workflows: QIAGEN continued expanding its genomic and bioinformatics capabilities, with clinical applications and data-science activities showing double-digit growth indicators during 2025. The development highlights the increasing role of software, interpretation, and genomic knowledge in translating molecular testing into actionable healthcare information. Approximately 7% of market development activity is linked to bioinformatics integration, while around 5% reflects growing demand for clinical genomic interpretation.
Report Coverage
The Pharmacogenomics Market report covers market development across major technology and application categories, including DNA Sequencing, Microarray, Polymerase Chain Reaction, Electrophoresis, Mass Spectrometry, and Others. Application analysis includes Drug Discovery, Tailored Treatment, Oncology, Pain Management, and Other Therapeutic Applications. The assessment also examines regional dynamics across North America, Europe, Asia-Pacific, and Middle East & Africa, with regional shares structured to represent 100% of the global market. Competitive coverage includes Abbott Laboratories, Inc, Bayer AG, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche AG, Becton, Dickinson and Company, Illumina, Inc., Bio-Rad Laboratories, Inc., and QIAGEN. The analysis considers technology adoption, clinical integration, laboratory automation, precision-medicine implementation, reimbursement conditions, testing accessibility, and competitive product development. Approximately 10% of market activity is associated with advanced genomic technologies, while around 7% reflects increasing clinical integration. The coverage further evaluates opportunities, drivers, restraints, challenges, investment priorities, product-development trends, and recent manufacturer developments to provide a structured view of the market's competitive and operational environment.
Pharmacogenomics Market Report Coverage
| REPORT COVERAGE | DETAILS | |
|---|---|---|
|
Market Size Value In |
USD 9155.33 Million in 2026 |
|
|
Market Size Value By |
USD 21190.89 Million by 2035 |
|
|
Growth Rate |
CAGR of 9.77% from 2026 - 2035 |
|
|
Forecast Period |
2026 - 2035 |
|
|
Base Year |
2025 |
|
|
Historical Data Available |
Yes |
|
|
Regional Scope |
Global |
|
|
Segments Covered |
By Type :
By Application :
|
|
|
To Understand the Detailed Market Report Scope & Segmentation |
||
Download FREE Sample
Frequently Asked Questions
-
What value is the Pharmacogenomics Market expected to touch by 2035?
The global Pharmacogenomics Market is expected to reach USD 21190.89 Million by 2035.
-
What CAGR is the Pharmacogenomics Market expected to exhibit by 2035?
The Pharmacogenomics Market is expected to exhibit a CAGR of 9.77% by 2035.
-
Who are the top players in the Pharmacogenomics Market?
Abbott Laboratories, Inc, Bayer AG, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche AG, Becton, Dickinson and Company, Illumina, Inc., Bio-Rad Laboratories, Inc., QIAGEN
-
What was the value of the Pharmacogenomics Market in 2025?
In 2025, the Pharmacogenomics Market value stood at USD 8340.5 Million.
About the Author(s):
This report was authored by the Healthcare Research Team at Global Growth Insights. The team specializes in pharmaceuticals, biotechnology, medical devices, diagnostics, digital health, healthcare services, and life sciences. Their expertise includes market sizing, regulatory analysis, competitive benchmarking, and healthcare trend forecasting to support strategic investment and business growth.
Our Clients
Download FREE Sample